Biography of Prof. David Lyden

We are proud to announce that Prof. David Lyden will be a keynote speaker at NLSEV-2021. Please find below his biography.


Dr. Lyden completed his M.D. at Brown University, Ph.D. at the University of Vermont, residency in Pediatrics at Duke University Medical Center, and fellowship in Pediatric Hematology/Oncology at Memorial Sloan Kettering Cancer Center. Currently, he is the Stavros S. Niarchos Professor of Pediatrics and Cell and Developmental Biology at Weill Cornell Medicine/Cornell University in New York City.

Early work in Dr. Lyden's laboratory resulted in several fundamental discoveries demonstrating that bone marrow-derived endothelial and hematopoietic progenitors participate in the formation of new blood vessels in the primary tumor. Dr. Lyden showed that factors secreted by the primary tumor prime certain tissues for tumor cell engraftment. He defined the concept of the "pre-metastatic niche" (PMN), where newly recruited bone marrow-derived myeloid progenitor cells collaborate with other cells types residing in the tissue parenchyma to provide a platform for assembly of the metastatic lesion. Dr. Lyden's then went on to demonstrate that tumor-derived exosomes initiate the PMN by educating stromal cells and bone marrow progenitor cells, promoting metastasis. He identified key proteins and the presence of nucleic acids, specifically double stranded DNA, in exosomes and demonstrated that this exosomal cargo supports thrombosis, vascular leakiness, and PMN formation. Recently, he has defined the role of tumor exosomal integrins in organotropic metastasis, and has developed novel technologies to dissect the physical and functional heterogeneity of exosome populations, discovering a new nanoparticle, the exomere, which is the most abundant tumor-secreted particle, with distinct functional roles in mediating the systemic effects of cancer. Moreover, Dr. Lyden is a recipient of the prestigious National Institutes of Health R35 Outstanding Investigator Award, that supports his efforts to explore the systemic effects of metastatic cancer.